Search

Your search keyword '"Sgourou, Argyro"' showing total 162 results
Start Over Author "Sgourou, Argyro"
162 results on '"Sgourou, Argyro"'

4. Implementation and Evaluation of a Three-Dimensional Virtual Reality Biology Lab versus Conventional Didactic Practices in Lab Experimenting with the Photonic Microscope

Author

Paxinou, Evgenia, Panagiotakopoulos, Christos T., Karatrantou, Anthi, Kalles, Dimitrios, and Sgourou, Argyro

Abstract

This study presents the integration of three different teaching scenarios, during biology laboratory lessons, with the overall aim of exploring the potential predominant effectiveness of teaching and improvement of students' learning, by the use of the three-dimensional virtual reality educational tool Onlabs, versus more traditional didactic practices. A sample of 83, fourth year, undergraduate students of the Primary Education Department of Patras' University in Greece, were equally separated into three cognitively balanced groups to be educated on the light microscopy experiment by three different educational scenarios. Students' conceptual understanding in the domain of microscopy, was evaluated during all learning procedure with Pre and Post tests, whereas their skill to handle properly a real light microscope in the wet biology lab was summatively assessed via a specially designed work sheet. Results of the present study provide evidence in favor of the virtual reality application.

Published
2020
Full Text
View/download PDF

10. Developmental Dyslexia: Insights from EEG-Based Findings and Molecular Signatures—A Pilot Study.

Author

Theodoridou, Daniela, Tsiantis, Christos-Orestis, Vlaikou, Angeliki-Maria, Chondrou, Vasiliki, Zakopoulou, Victoria, Christodoulides, Pavlos, Oikonomou, Emmanouil D., Tzimourta, Katerina D., Kostoulas, Charilaos, Tzallas, Alexandros T., Tsamis, Konstantinos I., Peschos, Dimitrios, Sgourou, Argyro, Filiou, Michaela D., and Syrrou, Maria

Subjects
DYSLEXIA, LEARNING disabilities, GLUCOCORTICOID receptors, PILOT projects, SCHOOL environment
Abstract

Developmental dyslexia (DD) is a learning disorder. Although risk genes have been identified, environmental factors, and particularly stress arising from constant difficulties, have been associated with the occurrence of DD by affecting brain plasticity and function, especially during critical neurodevelopmental stages. In this work, electroencephalogram (EEG) findings were coupled with the genetic and epigenetic molecular signatures of individuals with DD and matched controls. Specifically, we investigated the genetic and epigenetic correlates of key stress-associated genes (NR3C1, NR3C2, FKBP5, GILZ, SLC6A4) with psychological characteristics (depression, anxiety, and stress) often included in DD diagnostic criteria, as well as with brain EEG findings. We paired the observed brain rhythms with the expression levels of stress-related genes, investigated the epigenetic profile of the stress regulator glucocorticoid receptor (GR) and correlated such indices with demographic findings. This study presents a new interdisciplinary approach and findings that support the idea that stress, attributed to the demands of the school environment, may act as a contributing factor in the occurrence of the DD phenotype. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Adventure-Style Serious Game for a Science Lab

Author

Zafeiropoulos, Vasilis, Kalles, Dimitris, Sgourou, Argyro, Kameas, Achilleas, Hutchison, David, Series editor, Kanade, Takeo, Series editor, Kittler, Josef, Series editor, Kleinberg, Jon M., Series editor, Kobsa, Alfred, Series editor, Mattern, Friedemann, Series editor, Mitchell, John C., Series editor, Naor, Moni, Series editor, Nierstrasz, Oscar, Series editor, Pandu Rangan, C., Series editor, Steffen, Bernhard, Series editor, Terzopoulos, Demetri, Series editor, Tygar, Doug, Series editor, Weikum, Gerhard, Series editor, Rensing, Christoph, editor, de Freitas, Sara, editor, Ley, Tobias, editor, and Muñoz-Merino, Pedro J., editor

Published
2014
Full Text
View/download PDF

18. Arsenic exposure promotes the emergence of cardiovascular diseases.

Author

Karachaliou, Christiana, Sgourou, Argyro, Kakkos, Stavros, and Kalavrouziotis, Ioannis

Abstract

A large number of studies conducted in the past decade 2010-2020 refer to the impact of arsenic (As) exposure on cardiovascular risk factors. The arsenic effect on humans is complex and mainly depends on the varying individual susceptibilities, its numerous toxic expressions and the variation in arsenic metabolism between individuals. In this review we present relevant data from studies which document the association of arsenic exposure with various biomarkers, the effect of several genome polymorphisms on arsenic methylation and the underling molecular mechanisms influencing the cardiovascular pathology. The corresponding results provide strong evidence that high and moderate-high As intake induce oxidative stress, inflammation and vessel endothelial dysfunction that are associated with increased risk for cardiovascular diseases (CVDs) and in particular hypertension, myocardial infarction, carotid intima-media thickness and stroke, ventricular arrhythmias and peripheral arterial disease. In addition, As exposure during pregnancy implies risks for blood pressure abnormalities among infants and increased mortality rates from acute myocardial infarction during early adulthood. Low water As concentrations are associated with increased systolic, diastolic and pulse pressure, coronary heart disease and incident stroke. For very low As concentrations the relevant studies are few. They predict a risk for myocardial infarction, stroke and ischemic stroke and incident CVD, but they are not in agreement regarding the risk magnitude. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

25. HLA Polymorphisms and Food Allergy Predisposition

Author

Kostara, Maria Chondrou, Vasiliki Sgourou, Argyro Douros, Konstantinos Tsabouri, Sophia

Abstract

Food allergy (FA) is a growing health problem that affects similar to 8% of the children worldwide. Although the prevalence of FA is increasing, the underlying genetic mechanisms responsible for the onset of this immune disorder are not yet clarified. Genetic factors seem to play a leading role in the development of FA, though interaction with environmental factors cannot be excluded. The broader network of genetic loci mediating the risk of this complex disorder remains to be identified. The human leucocyte antigen (HLA) has been associated with various immune disorders, including FA. This review aims to unravel the potential associations between HLA gene functions and the manifestation and outcome of FA disorders. Exploring new aspects of FA development with the perspective to improve our understanding of the multifaceted etiology and the complex biological mechanisms involved in FA is essential.

Published
2020

27. Analgesic effect of paracetamol monotherapy vs. the combination of paracetamol/parecoxib vs. the combination of pethidine/paracetamol in patients undergoing thyroidectomy

Author

Mulita, Francesk, primary, Verras, Georgios-Ioannis, additional, Iliopoulos, Fotios, additional, Kaplanis, Charalampos, additional, Liolis, Elias, additional, Tchabashvili, Levan, additional, Tsilivigkos, Christos, additional, Perdikaris, Ioannis, additional, Sgourou, Argyro, additional, Papachatzopoulou, Adamantia, additional, and Maroulis, Ioannis, additional

Published
2021
Full Text
View/download PDF

30. Role of Genomic Biomarkers in Increasing Fetal Hemoglobin Levels Upon Hydroxyurea Therapy and in β-Thalassemia Intermedia: A Validation Cohort Study

Author

Kolliopoulou, Alexandra, Siamoglou, Stavroula, John, Anne, Sgourou, Argyro, Kourakli, Alexandra, Argiris Symeonidis, Vlachaki, Efthymia, Chalkia, Panagiota, Theodoridou, Stamatia, Ali, Bassam R., Katsila, Theodora, Patrinos, George P., and Papachatzopoulou, Adamantia

Abstract

Hemoglobinopathies exhibit a remarkable phenotypic diversity in terms of disease severity, while individual genetic background plays a key role in differential response to drug treatment. In the last decade, genomic variants in genes located within, as well as outside the human β-globin cluster have been shown to be significantly associated with Hb F increase, in relation to hydroxyurea (HU) therapy in patients with these diseases. Here, we aim to determine the effect of genomic variants located in genes, such as MAP3K5, ASS1, NOS2A, TOX, PDE7B, NOS1, FLT1 and ARG2, previously shown to modulate fetal hemoglobin (Hb F) levels in patients with β type hemoglobinopathies and reflecting disease severity and response to HU therapy in an independent cohort of Greek patients with these diseases. We recruited and genotyped 45 β-thalassemia patients (β-thal), either transfusion-dependent (TDT) or non transfusion-dependent (NTDT), 42 Hb S (HBB: c.20A>T)-β-thal compound heterozygotes, who were treated with HU, as well as 53 healthy individuals, all of Hellenic origin. Our study showed that genomic variants of the MAP3K5, NOS2A and ARG2 gene are associated with HU therapy efficacy in Hb S-β-thal compound heterozygotes. We have also shown that FLT1 and ARG2 genomic variants are associated with the mild phenotype of NTDT patients. Our findings provide evidence that MAP3K5, NOS2A, ARG2 and FLT1 genomic variants could be considered as genomic biomarkers to predict HU therapy efficacy in Hb S-β-thal compound heterozygotes and also to describe disease severity in patients with β type hemoglobinopathies.

Published
2019
Full Text
View/download PDF

34. Association of genome variations in the renin-angiotensin system with physical performance

Author

Sgourou Argyro, Fotopoulos Vassilis, Kontos Vassilis, Patrinos George P, and Papachatzopoulou Adamantia

Subjects
Genetic variations, Renin-angiotensin system, Physical performance, Medicine, Genetics, QH426-470
Abstract

Abstract Background The aim of this study was to determine the genotype distribution and allelic frequencies of ACE (I/D), AGTR1 (A +1166 C), BDKRB2 (+9/−9) and LEP (G–2548A) genomic variations in 175 Greek athletes who excelled at a national and/or international level and 169 healthy Greek adults to identify whether some particular combinations of these loci might serve as predictive markers for superior physical condition. Results The D/D genotype of the ACE gene (p = 0.034) combined with the simultaneous existence of BDKRB2 (+9/−9) (p = 0.001) or LEP (G/A) (p = 0.021) genotypes was the most prevalent among female athletes compared to female controls. A statistical trend was also observed in BDKRB2 (+9/−9) and LEP (G–2548A) heterozygous genotypes among male and female Greek athletes, and in ACE (I/D) only in male athletes. Finally, both male and female athletes showed the highest rates in the AGTR1 (A/A) genotype. Conclusions Our results suggest that the co-existence of ACE (D/D), BDKRB2 (+9/−9) or LEP (G/A) genotypes in female athletes might be correlated with a superior level of physical performance.

Published
2012
Full Text
View/download PDF

36. Role of Genomic Biomarkers in Increasing Fetal Hemoglobin Levels Upon Hydroxyurea Therapy and in β-Thalassemia Intermedia: A Validation Cohort Study

Author

Kolliopoulou, Alexandra, primary, Siamoglou, Stavroula, additional, John, Anne, additional, Sgourou, Argyro, additional, Kourakli, Alexandra, additional, Symeonidis, Argiris, additional, Vlachaki, Efthymia, additional, Chalkia, Panagiota, additional, Theodoridou, Stamatia, additional, Ali, Bassam R., additional, Katsila, Theodora, additional, Patrinos, George P., additional, and Papachatzopoulou, Adamantia, additional

Published
2019
Full Text
View/download PDF

37. Additional file 1: Table S1. of Whole transcriptome analysis of human erythropoietic cells during ontogenesis suggests a role of VEGFA gene as modulator of fetal hemoglobin and pharmacogenomic biomarker of treatment response to hydroxyurea in β-type hemoglobinopathy patients

Author

Chondrou, Vasiliki, Kolovos, Petros, Sgourou, Argyro, Kourakli, Alexandra, Pavlidaki, Alexia, Vlasia Kastrinou, John, Anne, Argiris Symeonidis, Ali, Bassam, Papachatzopoulou, Adamantia, Katsila, Theodora, and Patrinos, George

Abstract

Upregulated genes when (i) peripheral blood is compared to umbilical cord blood and fetal liver (PB vs CB+FL) and (ii) peripheral blood is compared to fetal liver (PB vs FL). Table S2. Downregulated genes when (i) peripheral blood is compared to umbilical cord blood and fetal liver (PB vs CB+FL) and (ii) peripheral blood is compared to fetal liver (PB vs FL). Table S3. Statistical and Hardy-Weinberg analyses on the genotyping data of β-type hemoglobinopathy patients of Hellenic origin and healthy (non-thalassemic) individuals. Table S4. Pairwise linkage disequilibrium (LD) calculations for the tagSNPs of interest across the VEGFA gene (CEU). Figure S1. Differential gene expression when adult peripheral blood is compared to cord blood. A total of 135 genes were over- (FC > 2) or downregulated (FC 2) or downregulated (FC

Published
2017
Full Text
View/download PDF

38. Whole transcriptome analysis of human erythropoietic cells during ontogenesis suggests a role of VEGFA gene as modulator of fetal hemoglobin and pharmacogenomic biomarker of treatment response to hydroxyurea in β-type hemoglobinopathy patients

Author

Chondrou, Vasiliki, Kolovos, Petros, Sgourou, Argyro, Kourakli, Alexandra, Pavlidaki, Alexia, Kastrinou, Vlasia, John, Anne, Symeonidis, Argiris, Ali, Bassam R., Papachatzopoulou, Adamantia, Katsila, Theodora, Patrinos, George P., Chondrou, Vasiliki, Kolovos, Petros, Sgourou, Argyro, Kourakli, Alexandra, Pavlidaki, Alexia, Kastrinou, Vlasia, John, Anne, Symeonidis, Argiris, Ali, Bassam R., Papachatzopoulou, Adamantia, Katsila, Theodora, and Patrinos, George P.

Abstract

Background: Human erythropoiesis is characterized by distinct gene expression profiles at various developmental stages. Previous studies suggest that fetal-to-adult hemoglobin switch is regulated by a complex mechanism, in which many key players still remain unknown. Here, we report our findings from whole transcriptome analysis of erythroid cells, isolated from erythroid tissues at various developmental stages in an effort to identify distinct molecular signatures of each erythroid tissue. Results: From our in-depth data analysis, pathway analysis, and text mining, we opted to focus on the VEGFA gene, given its gene expression characteristics. Selected VEGFA genomic variants, identified through linkage disequilibrium analysis, were explored further for their association with elevated fetal hemoglobin levels in β-type hemoglobinopathy patients. Our downstream analysis of non-transfusion-dependent β-thalassemia patients, β-thalassemia major patients, compound heterozygous sickle cell disease/β-thalassemia patients receiving hydroxyurea as fetal hemoglobin augmentation treatment, and non-thalassemic individuals indicated that VEGFA genomic variants were associated with disease severity in β-thalassemia patients and hydroxyurea treatment efficacy in SCD/β-thalassemia compound heterozygous patients. Conclusions: Our findings suggest that VEGFA may act as a modifier gene of human globin gene expression and, at the same time, serve as a genomic biomarker in β-type hemoglobinopathy disease severity and hydroxyurea treatment efficacy.

Published
2017

39. Whole transcriptome analysis of human erythropoietic cells during ontogenesis suggests a role of VEGFA gene as modulator of fetal hemoglobin and pharmacogenomic biomarker of treatment response to hydroxyurea in β-type hemoglobinopathy patients

Author

Chondrou, Vasiliki, primary, Kolovos, Petros, additional, Sgourou, Argyro, additional, Kourakli, Alexandra, additional, Pavlidaki, Alexia, additional, Kastrinou, Vlasia, additional, John, Anne, additional, Symeonidis, Argiris, additional, Ali, Bassam R., additional, Papachatzopoulou, Adamantia, additional, Katsila, Theodora, additional, and Patrinos, George P., additional

Published
2017
Full Text
View/download PDF

40. Mechanical stress affects methylation pattern of GNAS isoforms and osteogenic differentiation of hAT-MSCs

Author

Vlaikou, Angeliki-Maria, primary, Kouroupis, Dimitrios, additional, Sgourou, Argyro, additional, Markopoulos, Georgios S., additional, Bagli, Eleni, additional, Markou, Maria, additional, Papadopoulou, Zoe, additional, Fotsis, Theodore, additional, Nakos, Georgios, additional, Lekka, Maria-Eleni E., additional, and Syrrou, Maria, additional

Published
2017
Full Text
View/download PDF

42. Correlation of SIN3A Genomic Variants with β-Hemoglobinopathies Disease Severity and Hydroxyurea Treatment Efficacy

Author

Gravia, Aikaterini, primary, Chondrou, Vasiliki, additional, Kolliopoulou, Alexandra, additional, Kourakli, Alexandra, additional, John, Anne, additional, Symeonidis, Argyris, additional, Ali, Bassam R, additional, Sgourou, Argyro, additional, Papachatzopoulou, Adamantia, additional, Katsila, Theodora, additional, and Patrinos, George P, additional

Published
2016
Full Text
View/download PDF

43. Genomic variants in the ASS1 gene, involved in the nitric oxide biosynthesis and signaling pathway, predict hydroxyurea treatment efficacy in compound sickle cell disease/β-thalassemia patients

Author

Chalikiopoulou, Constantina, primary, Tavianatou, Anastasia-Gerasimoula, additional, Sgourou, Argyro, additional, Kourakli, Alexandra, additional, Kelepouri, Dimitra, additional, Chrysanthakopoulou, Maria, additional, Kanelaki, Vasiliki-Kaliopi, additional, Mourdoukoutas, Evangelos, additional, Siamoglou, Stavroula, additional, John, Anne, additional, Symeonidis, Argyris, additional, Ali, Bassam R, additional, Katsila, Theodora, additional, Papachatzopoulou, Adamantia, additional, and Patrinos, George P, additional

Published
2016
Full Text
View/download PDF

44. Genomic Variants in Members of the Krüppel-Like Factor Gene Family are Associated with Disease Severity and Hydroxyurea Treatment Efficacy in β-Hemoglobinopathies Patients

Author

Stratopoulos, Apostolos, Kolliopoulou, Alexandra, Karamperis, Kariofyllis, John, Anne, Kydonopoulou, Kyriaki, Esftathiou, George, Sgourou, Argyro, Kourakli, Alexandra, Vlachaki, Efthimia, Chalkia, Panagiota, Theodoridou, Stamatia, Papadakis, Manoussos N, Gerou, Spyridon, Symeonidis, Argiris, Katsila, Theodora, Ali, Bassam R, Papachatzopoulou, Adamantia, and Patrinos, George P

Abstract

Aim:β-Type hemoglobinopathies are characterized by vast phenotypic diversity as far as disease severity is concerned, while differences have also been observed in hydroxyurea (HU) treatment efficacy. These differences are partly attributed to the residual expression of fetal hemoglobin (HbF) in adulthood. The Krüppel-like family of transcription factors (KLFs) are a set of zinc finger DNA-binding proteins which play a major role in HbF regulation. Here, we explored the possible association of variants in KLFgene family members with response to HU treatment efficacy and disease severity in β-hemoglobinopathies patients. Materials & methods:Six tag single nucleotide polymorphisms, located in four KLFgenes, namely KLF3, KLF4, KLF9and KLF10, were analyzed in 110 β-thalassemia major patients (TDT), 18 nontransfusion dependent β-thalassemia patients (NTDT), 82 sickle cell disease/β-thalassemia compound heterozygous patients and 85 healthy individuals as controls. Results:Our findings show that a KLF4genomic variant (rs2236599) is associated with HU treatment efficacy in sickle cell disease/β-thalassemia compound heterozygous patients and two KLF10genomic variants (rs980112, rs3191333) are associated with persistent HbF levels in NTDT patients. Conclusion:Our findings provide evidence that genomic variants located in KLF10gene may be considered as potential prognostic biomarkers of β-thalassemia clinical severity and an additional variant in KLF4gene as a pharmacogenomic biomarker, predicting response to HU treatment.

Published
2019
Full Text
View/download PDF

45. Impact of ZBTB7Ahypomethylation and expression patterns on treatment response to hydroxyurea

Author

Chondrou, Vasiliki, Stavrou, Eleana, Markopoulos, Georgios, Kouraklis-Symeonidis, Alexandra, Fotopoulos, Vasilios, Symeonidis, Argiris, Vlachaki, Efthymia, Chalkia, Panagiota, Patrinos, George, Papachatzopoulou, Adamantia, and Sgourou, Argyro

Abstract

We aimed to clarify the emerging epigenetic landscape in a group of genes classified as “modifier genes” of the β-type globin genes (HBBcluster), known to operate in transto accomplish the two natural developmental switches in globin expression, from embryonic to fetal during the first trimester of conception and from fetal to adult around the time of birth. The epigenetic alterations were determined in adult sickle cell anemia (SCA) homozygotes and SCA/β-thalassemia compound heterozygotes of Greek origin, who are under hydroxyurea (HU) treatment. Patients were distinguished in HU responders and HU non-responders (those not benefited from the HU) and both, and in vivo and in vitro approaches were implemented. We examined the CpG islands’ DNA methylation profile of BCL11A, KLF1, MYB, MAP3K5, SIN3A, ZBTB7A, and GATA2, along with γ-globin and LRF/ZBTB7Aexpression levels. In vitro treatment of hematopoietic stem cells (HSCs) with HU induced a significant DNA hypomethylation pattern in ZBTB7A(p*, 0.04) and GATA2(p*, 0.03) CpGs exclusively in the HU non-responders. Also, this group of patients exhibited significantly elevated baseline methylation patterns in ZBTB7A, before the HU treatment, compared to HU responders (p*, 0.019) and to control group of healthy individuals (p*, 0.021), which resembles a potential epigenetic barrier for the γ-globin expression. γ-Globin expression in vitro matched with detected HbF levels during patients’ monitoring tests (in vivo) under HU treatment, implying a good reproducibility of the in vitro HU epigenetic effect. LRF/ZBTB7Aexpression was elevated only in the HU non-responders under the influence of HU. This is one of the very first pharmacoepigenomic studies indicating that the hypomethylation of ZBTB7Aduring HU treatment enhances the LRF expression, which by its turn suppresses the HbF resumption in the HU non-responders. Its role as an epigenetic regulator of hemoglobin switching is also supported by the wide distribution of ZBTB7A-binding sites within the 5′ CpG sequences of all studied human HBBcluster “modifier genes.” Also, the baseline methylation level of selective CpGs in ZBTB7Aand GATA2could be an indicator of the negative HU response among the β-type hemoglobinopathy patients.

Published
2018
Full Text
View/download PDF

49. Whole transcriptome analysis of human erythropoietic cells during ontogenesis suggests a role of VEGFAgene as modulator of fetal hemoglobin and pharmacogenomic biomarker of treatment response to hydroxyurea in β-type hemoglobinopathy patients

Author

Chondrou, Vasiliki, Kolovos, Petros, Sgourou, Argyro, Kourakli, Alexandra, Pavlidaki, Alexia, Kastrinou, Vlasia, John, Anne, Symeonidis, Argiris, Ali, Bassam, Papachatzopoulou, Adamantia, Katsila, Theodora, and Patrinos, George

Abstract

Human erythropoiesis is characterized by distinct gene expression profiles at various developmental stages. Previous studies suggest that fetal-to-adult hemoglobin switch is regulated by a complex mechanism, in which many key players still remain unknown. Here, we report our findings from whole transcriptome analysis of erythroid cells, isolated from erythroid tissues at various developmental stages in an effort to identify distinct molecular signatures of each erythroid tissue. From our in-depth data analysis, pathway analysis, and text mining, we opted to focus on the VEGFAgene, given its gene expression characteristics. Selected VEGFAgenomic variants, identified through linkage disequilibrium analysis, were explored further for their association with elevated fetal hemoglobin levels in β-type hemoglobinopathy patients. Our downstream analysis of non-transfusion-dependent β-thalassemia patients, β-thalassemia major patients, compound heterozygous sickle cell disease/β-thalassemia patients receiving hydroxyurea as fetal hemoglobin augmentation treatment, and non-thalassemic individuals indicated that VEGFAgenomic variants were associated with disease severity in β-thalassemia patients and hydroxyurea treatment efficacy in SCD/β-thalassemia compound heterozygous patients. Our findings suggest that VEGFAmay act as a modifier gene of human globin gene expression and, at the same time, serve as a genomic biomarker in β-type hemoglobinopathy disease severity and hydroxyurea treatment efficacy.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results